Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 21 versus JENCYCLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 21 versus JENCYCLA.
GENCEPT 10/11-21 vs JENCYCLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
None Documented
None Documented
Terminal elimination half-life is 24-30 hours; allows once-daily dosing; steady-state achieved in 5-7 days
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Renal (30-40% as unchanged drug and metabolites), biliary/fecal (50-60% as metabolites)
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive